We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+14.74%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$792M
AUM Growth
+$9.15M
Cap. Flow
+$37.1M
Cap. Flow %
4.68%
Top 10 Hldgs %
65.85%
Holding
54
New
9
Increased
12
Reduced
17
Closed
8

Top Buys

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$65.8M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$10.6M
3
FOLD
Amicus Therapeutics
FOLD
+$8.72M
4
ASND icon
Ascendis Pharma A/S
ASND
+$7.66M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$5.13M

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$30.3M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$28.3M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$17.1M
4
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$14.1M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 65.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
51
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-125,800
Closed -$258K
TRIL
52
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-227,399
Closed -$1.4M
AVXS
53
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-225,370
Closed -$17.1M
1 2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Avoro Capital Advisors held 54 positions worth $792M, up 1.2% from $783M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Avoro Capital Advisors deployed $37.1M of net new capital in Q2 2017, opening 9 new positions and adding to 12 existing holdings. Its largest new stake was Kite Pharma, Inc.: 806,750 shares worth $83.6M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 75% a quarter earlier.

On the sell side, the largest reduction was Acadia Pharmaceuticals, an estimated $30.3M trimmed.

  • Avoro Capital Advisors's largest Q2 2017 buy was Kite Pharma, Inc.: 806,750 shares worth $83.6M.
  • Avoro Capital Advisors added most to Amicus Therapeutics in Q2 2017, an estimated $8.72M increase.
  • Avoro Capital Advisors's biggest Q2 2017 reduction was Acadia Pharmaceuticals, cutting an estimated $30.3M.
  • Avoro Capital Advisors fully exited Seagen Inc. Common Stock in Q2 2017, selling an estimated $28.3M.
  • Avoro Capital Advisors's ten largest holdings make up 66% of its $792M portfolio in Q2 2017.
  • Avoro Capital Advisors opened 9 new positions and closed 8 in Q2 2017.
  • Avoro Capital Advisors's portfolio value rose 1.2% quarter-over-quarter to $792M.

Based on Avoro Capital Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.